Pfizer Inc. (PFE)
| Market Cap | 137.11B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.67B |
| EPS (ttm) | 1.38 |
| PE Ratio | 17.48 |
| Forward PE | 8.34 |
| Dividend | $1.72 (7.12%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 25,669,353 |
| Open | 24.20 |
| Previous Close | 23.79 |
| Day's Range | 23.99 - 24.37 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.51 |
| Analysts | Hold |
| Price Target | 30.36 (+25.58%) |
| Earnings Date | Apr 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $30.36, which is an increase of 25.58% from the latest price.
News
Pfizer's Q1 Update May Mark A Bottom In The Stock
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitabilit...
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Final Trade: XLF, ORLY, PFE, UBER
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pfizer could make ‘tremendous investments' in the US, but here's why it's choosing not to
Pfizer Inc. (NYSE: PFE) chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in ...
Pfizer Inc. (PFE) Q1 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE) Q1 2025 Results Conference Call April 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investment Relations Officer and Senior Vice President Dr. Albert Bo...
Pfizer's 7% Yield Makes It Look Like a Junk Bond—But Better
The big decline in Pfizer's share price may have a silver lining.
Stocks on the move: Pfizer and Uber
Pfizer's down after earnings — and Josh Brown, CEO of Ritholtz Wealth Management, is making moves. Hear why he's trimming Pfizer and what he sees in Uber!
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.
Breaking down Pfizer's first quarter earnings results, tariff impacts
Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 ...
Pfizer's plunging Paxlovid sales impact revenue as COVID fades
Pfizer Inc.'s stock moved lower in premarket trading on Tuesday after the drugmaker fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading de...
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
Pfizer Revenue Slides as Paxlovid Sales Fade
Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories.
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
Pfizer expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling Covid revenue. The cuts aim to help the pha...
Pfizer misses quarterly sales estimates as COVID treatment revenue falls
U.S. drugmaker Pfizer reported first-quarter revenue below Wall Street estimates on Tuesday, hurt by a decline in sales of its COVID antiviral treatment, Paxlovid.
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chair...
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.
Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings
Pfizer's Q1 earnings release is a prime opportunity to secure about a 7.55% dividend yield, with revenue stabilizing post-pandemic and strong cost efficiency. Pfizer's robust product pipeline and cons...
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry'...
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the de...
Pfizer Declares Second-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to ho...
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual M...
Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential obesi...